Fair opening price February 1, 2022 Current price
----------------------------------- -------------------
$70.93 $71.57 (Overvalued)
Why is Sarepta stock down?
Sarepta Therapeutics stock is falling after the biotech company said it would sell more stock and provided an update on product revenue. Sarepta stock was a darling of Wall Street in 2018, when the company first released positive data on its gene therapy for Duchenne Muscle Dystrophy.
What kind of company is Sarepta?
biotechnology company
What does Sarepta Therapeutics do?
Sarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. We are in a daily race to save lives stolen or impacted by rare disease.
What type of therapy is Eteplirsen?
Eteplirsen (brand name Exondys 51) is a medication to treat, but not cure, some types of Duchenne muscular dystrophy (DMD), caused by a specific mutation. Eteplirsen only targets specific mutations and can be used to treat about 14% of DMD cases. Eteplirsen is a form of antisense therapy.
Is Sarepta a good place to work?
Is Sarepta Therapeutics a good company to work for? Sarepta Therapeutics has an overall rating of 3.6 out of 5, based on over 80 reviews left anonymously by employees. 69% of employees would recommend working at Sarepta Therapeutics to a friend and 68% have a positive outlook for the business.3 days ago
Is Casimersen gene therapy?
Casimersen is a type of gene therapy known as an antisense oligonucleotide, which can cause the protein-making machinery in a cell to skip over exon 45 in the dystrophin gene.
How many employees does Sarepta have?
Sarepta Therapeutics Annual Number of Employees
-----------------------------------------------
2020
2019
2018
2017
Is numerator a good place to work?
Working at Numerator has been a good experience overall. The environment was very relaxed and fun. However, My work hours were long and it felt like I spent more time at work than at home. Even with the long hours, I was at times ask to stay beyond my shift to complete deadlines as well.
When was Sarepta founded?
, Corvallis, OR
How many employees work for Sarepta?
As of the end of 2018, Sarepta had 499 employees, including 255 working in R&D and 48 in sales. The company's total headcount is now tracking to about 900 by the end of 2019, Ingram told investors during the firm's second-quarter earnings call in August.
Where is Sarepta based?
Cambridge, Massachusetts
Is Sarepta a good stock to buy?
Sarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.